Pegasus Partners Ltd. Sells 1,613 Shares of Eli Lilly and Co (LLY)

Pegasus Partners Ltd. cut its position in shares of Eli Lilly and Co (NYSE:LLY) by 7.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 20,014 shares of the company’s stock after selling 1,613 shares during the quarter. Pegasus Partners Ltd.’s holdings in Eli Lilly and were worth $1,712,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of LLY. Virginia Retirement Systems ET AL boosted its position in shares of Eli Lilly and by 2.5% in the third quarter. Virginia Retirement Systems ET AL now owns 534,420 shares of the company’s stock worth $45,714,000 after acquiring an additional 12,900 shares during the last quarter. Legal & General Group Plc boosted its position in shares of Eli Lilly and by 1.8% in the third quarter. Legal & General Group Plc now owns 5,194,829 shares of the company’s stock worth $444,327,000 after acquiring an additional 93,633 shares during the last quarter. Great West Life Assurance Co. Can boosted its position in shares of Eli Lilly and by 4.9% in the third quarter. Great West Life Assurance Co. Can now owns 993,282 shares of the company’s stock worth $84,293,000 after acquiring an additional 46,679 shares during the last quarter. Nordea Investment Management AB boosted its position in shares of Eli Lilly and by 4.2% in the third quarter. Nordea Investment Management AB now owns 449,995 shares of the company’s stock worth $38,493,000 after acquiring an additional 18,197 shares during the last quarter. Finally, ETRADE Capital Management LLC boosted its position in shares of Eli Lilly and by 9.4% in the third quarter. ETRADE Capital Management LLC now owns 20,502 shares of the company’s stock worth $1,753,000 after acquiring an additional 1,754 shares during the last quarter. Institutional investors and hedge funds own 76.30% of the company’s stock.

Several equities research analysts recently issued reports on the stock. BMO Capital Markets set a $73.00 target price on shares of Eli Lilly and and gave the stock a “sell” rating in a research report on Tuesday, December 5th. Jefferies Group reissued a “buy” rating and issued a $89.00 target price on shares of Eli Lilly and in a research report on Thursday, August 31st. Leerink Swann raised their target price on shares of Eli Lilly and from $92.00 to $93.00 and gave the stock a “market perform” rating in a research report on Monday, October 23rd. Piper Jaffray Companies reissued an “overweight” rating and issued a $105.00 target price (up from $103.00) on shares of Eli Lilly and in a research report on Friday, September 8th. Finally, Credit Suisse Group reissued a “hold” rating on shares of Eli Lilly and in a research report on Wednesday, December 13th. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have assigned a buy rating to the company. Eli Lilly and currently has a consensus rating of “Hold” and an average target price of $90.25.

In other news, SVP Susan Mahony sold 36,585 shares of Eli Lilly and stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $86.18, for a total transaction of $3,152,895.30. Following the sale, the senior vice president now owns 54,885 shares in the company, valued at $4,729,989.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Lilly Endowment Inc sold 195,000 shares of Eli Lilly and stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $85.14, for a total transaction of $16,602,300.00. Following the sale, the insider now owns 123,513,247 shares in the company, valued at approximately $10,515,917,849.58. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 651,088 shares of company stock worth $56,439,586. 0.20% of the stock is currently owned by corporate insiders.

Eli Lilly and Co (NYSE LLY) opened at $84.99 on Wednesday. The firm has a market cap of $93,670.16, a P/E ratio of 40.28, a price-to-earnings-growth ratio of 1.76 and a beta of 0.35. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38. Eli Lilly and Co has a 12-month low of $72.97 and a 12-month high of $89.09.

Eli Lilly and (NYSE:LLY) last announced its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, beating analysts’ consensus estimates of $1.03 by $0.02. The firm had revenue of $5.66 billion for the quarter, compared to analysts’ expectations of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. Eli Lilly and’s revenue was up 9.0% compared to the same quarter last year. During the same period in the previous year, the company posted $0.88 earnings per share. equities research analysts predict that Eli Lilly and Co will post 4.22 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 9th. Shareholders of record on Thursday, February 15th will be given a dividend of $0.5625 per share. This represents a $2.25 dividend on an annualized basis and a yield of 2.65%. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend is Wednesday, February 14th. Eli Lilly and’s payout ratio is 98.58%.

ILLEGAL ACTIVITY NOTICE: “Pegasus Partners Ltd. Sells 1,613 Shares of Eli Lilly and Co (LLY)” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.com-unik.info/2017/12/27/pegasus-partners-ltd-sells-1613-shares-of-eli-lilly-and-co-lly.html.

Eli Lilly and Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

What are top analysts saying about Eli Lilly and? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Eli Lilly and and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit